Clinical trials: Cardiotoxicity
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Neoplasm Malignant Primary
TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography
TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer…
- Trial name
- TRUST-ACE (NCT06310330)
- Testing
- Comprehensive echocardiographic follow-up, Simplified echocardiographic follow-up
- Where
- Norway
- Volunteers
- 250 people
- Sponsor
- Norwegian University of Science and Technology
Anthracycline Induced Cardiotoxicity
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk.
- Trial name
- NCT04852965
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Queen's University, Belfast
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
Heart Failure, Cardiotoxicity
The STOP-MED CTRCD Trial
Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients.
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity
- Trial name
- STOP-MED CTRCD (NCT06183437)
- Testing
- Stopping Heart Failure Medication(s)
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 335 people
- Sponsor
- Dinesh Thavendiranathan
Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
The goal of this observational study is to learn about the long-term effects of anthracycline chemotherapy on inflammation, oxidative stress, and heart function in adult women with breast cancer.
- Conditions
- Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer
- Trial name
- ANTIOX-10 (NCT07680855)
- Volunteers
- 17 people
- Sponsor
- University of Chile
Anthracycline Related Cardiotoxicity in Breast Cancer
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function.
- Trial name
- NCT03934905
- Testing
- sulforaphane
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Texas Tech University Health Sciences Center
Cardiotoxicity
Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.
To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
- Trial name
- NCT07663357
- Where
- 6 sites in Brazil
- Volunteers
- 1,000 people
- Sponsor
- Beneficência Portuguesa de São Paulo
Breast Cancer
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
The activity of trastuzumab in early-stage, HER2-positive breast cancer, has been demonstrated in many studies, with meta-analyses showing that in combination with a variety of chemotherapy backbones, trastuzumab reduces the risk…
- Trial name
- NCT04928261
- Testing
- Trastuzumab
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Ottawa Hospital Research Institute
Cardiotoxicity
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
EMPACT (EMPAgliflozin in prevention of chemotherapy-related CardioToxicity) study is a randomized, multi-center, placebo-controlled, double-blind trial to evaluate efficacy of empagliflozin in prevention of left ventricular (LV)…
- Trial name
- EMPACT (NCT05271162)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 220 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Anthracyclines-Induced Cardiotoxicity, Cardiotoxicity
Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity
Anthracyclines, such as doxorubicin, are effective anticancer agents but may cause dose-dependent cardiac injury, including early changes in left ventricular function and cardiac biomarkers.
- Trial name
- DAPA-AIC (NCT06888505)
- Testing
- Dapagliflozin (Forxiga)
- Where
- Iraq
- Volunteers
- 94 people
- Sponsor
- Hawler Medical University
Cardiotoxicity, Toxicity Due to Chemotherapy
Pilot Study of an NTproBNP Guided Strategy of Cardioprotection
Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.
- Conditions
- Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma
- Trial name
- NTproBNP-Guide (NCT04737265)
- Testing
- Biomarker Guided Intervention
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cardiovascular Health, Breast Cancer
JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor.
- Conditions
- Cardiovascular Health, Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Cardio-oncology
- Trial name
- JUSTIFY (NCT06930521)
- Testing
- Intervention - Low Risk Group OR Intermediate Risk Group
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Women's College Hospital
Breast Cancer
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
The purpose of this study is to investigate whether cells from a biopsy taken from the patient skin can be transformed into cardiomyocytes the changes in cardiomyocyte (heart muscle cells) when grown in a special culture medium…
- Trial name
- NCT02772367
- Testing
- skin punch biopsy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Cardiac Dysfunction, Cardiovascular Diseases
Cardiac Dysfunction in Childhood Cancer Survivors
This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking…
- Conditions
- Cardiac Dysfunction, Cardiovascular Diseases, Childhood Cancer
- Trial name
- Cardio-Onco (NCT03790943)
- Testing
- cardiac assessment
- Where
- 6 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Leukemia, Cardiac Toxicity
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
It is now accepted that the anticancer properties of anthracyclines were allowed in many malignancies improve the prognosis of affected populations.
- Trial name
- CA2D (NCT01212926)
- Testing
- Echographic analysis of myocardial deformation in 2D strain
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Cardiotoxicity
A Study of Blood Pressure Control During Cancer Treatment
The purpose of this study to find out whether an intensive approach to treating high blood pressure during breast cancer treatment is safe and more effective than standard blood pressure treatment at lowering blood pressure…
- Trial name
- NCT06023576
- Testing
- antihypertensive medications, Blood pressure measurement, Echocardiogram
- Where
- 7 sites in United States
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center